JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB261802

Human ARL13B knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ARL13B KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 5 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.

View Alternative Names

ADP ribosylation factor like 13B, ADP ribosylation factor like 2 like 1, ADP-ribosylation factor-like protein 13B, ADP-ribosylation factor-like protein 2-like 1, AR13B_HUMAN, ARL2-like protein 1, ARL2L1, JBTS8

2 Images
Sanger Sequencing - Human ARL13B knockout HeLa cell line (AB261802)
  • Sanger seq

Unknown

Sanger Sequencing - Human ARL13B knockout HeLa cell line (AB261802)

Allele-2 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human ARL13B knockout HeLa cell line (AB261802)
  • Sanger seq

Unknown

Sanger Sequencing - Human ARL13B knockout HeLa cell line (AB261802)

Allele-1 : 5 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 5 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab261802-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261802 Human ARL13B knockout HeLa cell line", "number":"AB261802-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab261802-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261802 Human ARL13B knockout HeLa cell line", "number":"AB261802-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ARL13B
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ARL13B also known as ADP-ribosylation factor-like protein 13B is a small GTPase with a molecular mass of approximately 45 kDa. This protein predominantly localizes to the ciliary membrane of cells a specific structure important for cell signaling in eukaryotic organisms. Beyond its association with the cilia ARL13B expression is notable in complex neuronal tissues and renal epithelial cells indicating its diverse roles in various physiological processes.
Biological function summary

ARL13B plays an essential role in the formation and maintenance of primary cilia which are key to cell signaling and sensory processing. ARL13B functions as part of a multiprotein complex within the ciliary membrane essential for the localization and distribution of other ciliary proteins. Through its GTPase activity ARL13B regulates ciliary dynamics and signaling pathways that are fundamental to proper cellular function and development.

Pathways

ARL13B modulates the Sonic Hedgehog (Shh) and Wnt signaling pathways both critical in developmental processes and tissue homeostasis. ARL13B interacts with several proteins in these pathways to control signal transduction such as Gli proteins in the Shh pathway and various cytoplasmic and nuclear factors in the Wnt pathway. ARL13B's role as a signaling regulator highlights its importance in maintaining cellular communication and function.

Mutations or dysregulation of ARL13B are associated with Joubert syndrome and Meckel-Gruber syndrome both developmental disorders affecting the brain and other organs. These conditions arise partly from disrupted cilia function linking ARL13B directly to cilia-related syndromes. In Joubert syndrome ARL13B interacts with proteins such as Cep290 and IFT88 emphasizing its involvement in the pathology of ciliary dysfunctions and providing a focal point for understanding and potentially targeting these disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com